Broxaterol is a β2 adrenoreceptor agonist.[1] It is part of a class of drugs that affect the smooth muscle receptors in the body, often in use cases for respiratory disease that respond to this type of treatment.

Synthesis

The 1,3-dipolar cycloaddition between bromonitrile oxide, produced in situ from dibromoformaldoxime, and 3-butyn-2-one gives a mixture of isoxazoles, mainly the isomer shown required for broxaterol. Selective α-bromination of the acetyl group with pyridinium tribromide gives a bromoketone whose carbonyl group is reduced with sodium borohydride to produce a bromoethanol derivative. Treatment of this with tert-butylamine yields broxaterol.[2][3][4][5]

References

  1. ^ Nava S, Crotti P, Gurrieri G, Fracchia C, Rampulla C (January 1992). "Effect of a beta 2-agonist (broxaterol) on respiratory muscle strength and endurance in patients with COPD with irreversible airway obstruction". Chest. 101 (1): 133–40. doi:10.1378/chest.101.1.133. PMID 1345900. Archived from the original on 2013-04-14.
  2. ^ US patent 4276299, Davide Della Bella and Dario Chiarino, "1-(3-Bromo-isoxazol-5-yl)-2-tert.butylaminoethanol", issued 1981-06-30, assigned to Zambon SpA 
  3. ^ De Amici, Marco; De Micheli, Carlo; Carrea, Giacomo; Spezia, Sandro (1989). "Chemoenzymatic synthesis of chiral isoxazole derivatives". The Journal of Organic Chemistry. 54 (11): 2646–2650. doi:10.1021/jo00272a037.
  4. ^ Rohloff, John C.; Robinson, James; Gardner, John O. (1992). "Bromonitrile oxide [3+2] cycloadditions in water". Tetrahedron Letters. 33 (22): 3113–3116. doi:10.1016/S0040-4039(00)79827-3.
  5. ^ Battilocchio, Claudio; Bosica, Francesco; Rowe, Sam M.; et al. (2017). "Continuous Preparation and Use of Dibromoformaldoxime as a Reactive Intermediate for the Synthesis of 3-Bromoisoxazolines". Organic Process Research & Development. 21 (10): 1588–1594. doi:10.1021/acs.oprd.7b00229.


Allikas: https://en.wikipedia.org/wiki/Broxaterol
No tags for this post.